Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals — Investor Presentation (January 2018)

30 slides from Spectrum Pharmaceuticals's investor presentation, Jan 8, 2018

  1. Slide 1: Spectrum Pharmaceuticals Investor Presentation January 2018

    Spectrum Pharmaceuticals Joseph Turgeon President and Chief Executive Officer January 2018 Investor Presentation

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current b

  3. Slide 3: Mission

    Mission At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize pharmaceuticals for unmet medical needs while building value for our shareholders. Spectrum’s

  4. Slide 4: Poziotinib: Irreversible Tyrosine Kinase Inhibitor

    POZIOTINIB Irreversible Tyrosine Kinase Inhibitor

  5. Slide 5: Poziotinib is a Novel EGFR Tyrosine Kinase Inhibitor

    5 Poziotinib is a Novel EGFR Tyrosine Kinase Inhibitor  Orally available  Demonstrated activity in a variety of tumors  Recent data in exon 20 insertion mutations on NSCLC was promising

  6. Slide 6: Poziotinib's Lung Cancer Program Targets High Unmet Need

    6 Text here 0 10 20 30 40 50 0 20 40 60 80 100 Time (Months) Pr og re ss io n fre e su rv iv al (% o f p at ie nt s) Classical EGFR mutations (n=129) EGFR exon 20 insertions (n=9) Median PFS (mo) Classical EGFR Mutaions 14 EGFR exon 20 insertions 2 P<0.0001 (Log-rank) Per c ent Sur v iv a l Time (Mo

  7. Slide 7: Poziotinib Found Significantly More Potent than other EGFR Inhibitors

    7 Text here 0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 EGFR Exon20 Insertion Mutations log[Inhibitor], µM % V ia bi lit y AZD9291 EGF816 CO-1686 Afatinib Erlotinib Poziotinib 0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 EGFR Exon20 Insertion Mutations log[Inhibitor], µM % V ia b il it y AZD9291 EGF816

  8. Slide 8: Exon 20 Mutations Constrict the TKI Binding Pocket

    8 Text here The bulk and rigidity of first, second, and third generation TKIs prevent access to the restricted binding pocket Structural alterations restrict size of binding pocket Exon 20 Mutations in EGFR and HER2 Constricts the TKI Binding Pocket

  9. Slide 9: Poziotinib Binds Active Site and Blocks ATP

    9 Text here Poziotinib Binds Active Site and Blocks ATP Poziotinib Even with the restricted binding pocket of exon 20 insertion mutations, poziotinib is able to overcome steric hindrance allowing for irreversible binding

  10. Slide 10: MD Anderson Phase II Study of Poziotinib for EGFR Exon-20 Mutations

    1 0 MD Anderson Phase II Study of Poziotinib for EGFR Exon-20 Mutations Design Open-label, single center trial at MDACC  Cohort 1: EGFR exon 20 mutant NSCLC (N=50)  Cohort 2: Her2 exon 20 (N=30) Primary objective Assess objective response rate (ORR, RECIST 1.1) Secondary objectives PFS, OS, diseas

  11. Slide 11: Responses were seen in Patients who had Progression on Other TKIs

    1 1 Poziotinib -6 0 -4 5 -3 0 -1 5 0 1 5 3 0 4 5 M a x im u m R e s p o n s e f ro m B a s e lin e V 7 6 9 in s G S V H 7 7 3 in s A H H 7 7 3 d u p P R N 7 7 1 in s H H D 7 7 0 in s G P 7 7 2 in s D N P A 7 6 7 d u p A S V S 7 6 8 I S 7 6 8 d u p S V D D 7 7 0 d e l in s G Y D 7 7 0 in s Y H 7 7 3

  12. Slide 12: Preliminary Results Presented at the World Conference on Lung Cancer

    1 2 Preliminary Results Presented at the World Conference on Lung Cancer Activity:  8/11 PR observed; 2 patients have had additional follow up scans confirming PR  Duration of response not yet evaluable; only one patient with progressed disease thus far  Evidence of CNS activity in patient with C

  13. Slide 13: Example of Partial Response in Patient with Previous TKI use

    1 3 Text here Example of Partial Response in Patient with Previous TKI use (afatinib & AP32788) 8/4/2017 10/10/2017 Abstract ID 10369, Elamin et al. 18th IASLC World Conference on Lung Cancer 2017 Before Poziotinib After Poziotinib

  14. Slide 14: Multicenter Trial Enrolling Patients in Phase 2 Poziotinib Study

    1 4 Text here  We have initiated and are enrolling patients in a Phase 2 multi-center study at several leading cancer institutions in the U.S.  The study is enrolling up to 87 patients with EGFR exon 20 insertion mutations and up to 87 patients with HER2 exon 20 insertion mutations  The study wil

  15. Slide 15: Poziotinib Would Address a Significant Unmet Need

    1 5 Text here Poziotinib Would Address a Significant Unmet Need Advanced NSCLC patients ~131,000 EGFR cases ~16,300 10-15% 9-11% HER2 cases ~3,900 2-4% ~96% Advanced NSCLC patients ~224,000 EGFR cases ~28,000 HER2 cases ~6,700 2-4% ~96% Advanced NSCLC patients ~68,500 EGFR cases ~29,100 40-45% 9-11%

  16. Slide 16: Poziotinib Phase 2 Ongoing in HER2+ Breast Cancer Patients

    1 6  Open Label Phase 2 Study is enrolling patients  Entry Criteria include HER2- positive, metastatic breast cancer patients with at least 2 prior HER2-directed treatments  Primary Endpoint: Objective Response Rate (ORR)  Approximately 75 patients Poziotinib Phase 2 Ongoing in HER2+ Breast Canc

  17. Slide 17: ROLONTIS for the Management of Chemotherapy-Induced Neutropenia

    for the Management of Chemotherapy-Induced Neutropenia ROLONTIS™

  18. Slide 18: ROLONTIS: A Novel, Long-Acting GCSF

    1 8 ROLONTIS™ for the Management of Chemotherapy-Induced Neutropenia A Novel, Long-Acting GCSF

  19. Slide 19: ROLONTIS Phase 2 Efficacy: Median ANC Over Time in Cycle 1

    1 9 ROLONTIS Phase 2 Efficacy Median Absolute Neutrophil Count (ANC) Over Time in Cycle 1

  20. Slide 20: ROLONTIS Phase 2 Primary Endpoint: Days of Severe Neutropenia

    2 0 Text here ROLONTIS Phase 2 Primary Endpoint Days of Severe Neutropenia (DSN) in Cycle 1 ROLONTIS 45 µg/kg (N=39) ROLONTIS 135 µg/kg (N=36) ROLONTIS 270 µg/kg (N=36) Pegfilgrastim 6 mg (N=36) Days of Severe Neutropenia or DSN (Days) in Cycle 1 n 39 36 36 36 Mean 1.03 0.44 0.03 0.31 SD 1.547 1.275

  21. Slide 21: ROLONTIS Registration Program Includes Two Studies

    2 1 ADVANCE Registrational Study (n= ~400):  Enrollment completed August 2017  Topline results expected 1Q 2018 RECOVER International Study (n= ~218):  Similar study design  Enrolling in Europe and U.S. ROLONTIS Registration Program Includes Two Studies Expect to file U.S. BLA in 4Q 2018 and fil

  22. Slide 22: QAPZOLA: A Potent Tumor-activated Drug for Bladder Cancer

    A Potent Tumor-activated Drug for Bladder Cancer QAPZOLA®

  23. Slide 23: Bladder Cancer has a High Incidence, Recurrence, Cost and Unmet Need

    2 3  NMIBC remains an unmet medical need with no new drugs approved in the last 25 years  QAPZOLA demonstrated activity in previous studies and is well- tolerated  Most expensive cancer to treat with worldwide costs of over $5 billion  TURBT surgery is standard of care  60-70% of patients have

  24. Slide 24: QAPZOLA SPA from FDA on New Study Design

    2 4 New study design incorporates learnings from previous studies and recommendations from FDA Study Design  Approximately 425 patients  Single dose: 8mg  Intravesical Instillation at 60 +/- 30 minutes post TURBT  Double blind, placebo controlled Phase 3 study with 2:1 randomization  Low to int

  25. Slide 25: Advanced Stage Pipeline

    2 5 POZIOTINIB A Irreversible Tyrosine Kinase Inhibitor  Promising Activity in Lung Cancer Patients with Exon 20 Insertion Mutations  Multicenter Clinical Trial Initiated to Expedite Development Advanced Stage Pipeline ROLONTIS™ A Novel Long-acting GCSF for Chemotherapy-Induced Neutropenia  Top-L

  26. Slide 26: Thank You

    Thank You & SPECTRUM Redefining Cancer Care

  27. Slide 27: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In this press release, in historical “non-GAAP financial ” as defined in Regulation G of the Securities Exchange Act of 1934. Non-GAAP differ from financial in conformity to U.S. generally accepted accounting principles (oun In iecrdsics wih Regulation Gwe reconciled each

  28. Slide 28: GAAP to Non-GAAP reconciliation

    GAAP product sales, net & license fees and service revenue [Non-GAAP product sles, net & license fees and service revenue GAAPslling, general and administrative expenses ‘Non GAAP adjustments to SG&A: compensatce SGHA, ma GAAP loss per share (Basic and Diluted) ‘Non-GAAP loss per share (Basi and Dil

  29. Slide 29: Condensed Consolidated Statements of Operations

    SPECTRUM PHARMACEUTICALS, INC. ‘Condensed Consolidated Statements of Operations (Ga thousands, except per share Revenues: Product sales, net License fees and service revenue Total revenues Operating costs and expenses: ost of ales excludes amortization and impainnent charges of ‘Three Months Ended ‘

  30. Slide 30: orn: 94061, a 0,657 "

    orn: 94061, 740 a 0,657 " oo Pri ‘Accra ter cempehensive ince ) psy asi705) Tea ety STS ‘Tota ilies nd tock equity Sma £

Spectrum Pharmaceuticals — Investor Presentation (January 2018) on 6ix